Thymoglobulin

Thymoglobulin is a brand name for an equine antithymocyte globulin (ATG) preparation. It is a polyclonal antibody derived from horses that have been immunized with human T lymphocytes. Thymoglobulin is used primarily in the management of allograft rejection in patients undergoing organ transplantation, most commonly kidney transplants. It works by depleting T lymphocytes, which are key components of the immune system responsible for initiating and perpetuating the rejection process.

The administration of Thymoglobulin is typically intravenous. It is often used as part of an induction therapy regimen, meaning it is given before or shortly after transplantation to suppress the immune response and prevent acute rejection. It can also be used to treat acute cellular rejection that has already occurred. Due to its immunosuppressive nature, Thymoglobulin significantly increases the risk of opportunistic infections and other adverse events. Common side effects include fever, chills, rash, and hypotension. More serious reactions can include serum sickness, anaphylaxis, and hematologic abnormalities.

The dosage and duration of Thymoglobulin therapy are individualized based on the patient's clinical condition, transplant type, and concurrent immunosuppressive medications. Careful monitoring of the patient for efficacy and adverse effects is essential during treatment. Thymoglobulin is a potent immunosuppressant and its use requires careful consideration of the benefits versus the risks.